Answers are grounded in this paper and cite their sources.
Research shows regulatory T cells influence autoantigen presentation via pMHCII removal, suggesting therapeutic potential in autoimmunity.
Description Regulatory T cells (Tregs) maintain immune tolerance through mechanisms activated by T cell receptor (TCR) antigen recognition. Tregs bind antigen-presenting cells (APCs) with high avidity and remove cognate peptide-Major Histocompatibility Complex Class II (pMHCII) via processes akin to trogocytosis and transendocytosis. This selective suppression spares APCs’ ability to present other antigens while inhibiting effector CD4+ T cells that recognize the same pMHCII as Tregs in vivo. However, whether this mechanism operates in human Tregs and its potential for antigen-specific therapies remain unclear. To address this, we generated TCR-transduced human Tregs specific for the autoantigen glutamic acid decarboxylase (GAD) 65 peptide 555-567, presented by APCs expressing the autoimmunity-associated allele HLA–DRB1*04:01 (HLA-DR4). We demonstrated that GAD65-specific Tregs capture antigen from peptide-loaded HLA-DR4+ B cells and monocytes. Importantly, pMHCII removal was enhanced in Tregs with higher TCR affinity, highlighting their therapeutic potential. To study unmodified antigen-specific memory Tregs, we developed a novel sorting and expansion pipeline for bona fide antigen-specific Tregs from human PBMCs. Expanded Tregs similarly captured cognate pMHCII from autologous APCs, providing the first evidence of this mechanism in human Tregs. These findings suggest pMHCII depletion is a fundamental mechanism by which antigen-specific Tregs modulate autoantigen presentation.
No takes yet. Share an insight, caveat, or question.
Akkaya et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: